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Abstract  32 
Background 33 
Clinical management of Ebola Virus Disease (EVD) remains challenging. Routine laboratory analytics are 34 
often unavailable in the outbreak setting, and few data exist on the associated haematological and 35 
biochemical abnormalities. We present laboratory and clinical data from the Kerry Town Ebola Treatment 36 
Centre in Sierra Leone to better inform clinical management algorithms, improve understanding of key 37 
variables associated with outcome and provide insight into the pathophysiology of EVD.   38 
Methods 39 
150 patients with confirmed EVD were admitted between 8th December 2014 and 9th January 2015. At 40 
admission, all patients had clinical presentation recorded and blood taken for Ebola confirmation using 41 
reverse-transcriptase–polymerase-chain-reaction (RT-PCR) and for haematological and biochemical 42 
analysis. The association between these and clinical outcome was evaluated.  43 
Findings 44 
The mean age of cases was 26 years. Case fatality rate was 35% (55/150). Most patients presented with 45 
stage 2 (gastrointestinal involvement, 61%, 72/118) and stage 3 (severe/complicated, 10%, 12/118) 46 
disease. Acute Kidney injury (AKI) was common (50%, 52/104), as were abnormal serum potassium (33%, 47 
32/97), severe hepatitis (59%, 54/92) and raised CRP (21%, 21/100). Haematological abnormalities were 48 
common, including raised haematocrit (15%, 15/100), thrombocytopaenia (45%, 47/104) and 49 
granulocytosis (42%, 44/104). Severe AKI, low RT-PCR cycle threshold (<20 cycles) and severe hepatitis 50 
were independently associated with mortality. 51 
Interpretation 52 
EVD is associated with a high prevalence of haematological and biochemical abnormalities, even in mild 53 
disease and in the absence of gastrointestinal symptoms. Clinical care targeting hypovolaemia, electrolyte 54 
disturbance and AKI are likely to reduce historically high case fatality rates.  55 
Funding 56 
None 57 
 58 
  59 
Introduction  60 
Ebola virus disease (EVD) is caused by an RNA Filovirus, and is characterised by a febrile illness (87%), often 61 
progressing to diarrheoa (67%), vomiting (66%) and, sometimes, haemorrhage (18%).1 The current 62 
outbreak in West Africa is the largest the world has seen, with almost 25,000 cases (25th March 2015).2 63 
Clinical and public health management is challenging, especially in the worst hit countries of Sierra Leone, 64 
Liberia and Guinea, due to severity of clinical presentation, infection control concerns, poor health-system 65 
infrastructure and high population density.3,4  66 
  67 
There are currently no proven treatments for EVD, thus management is supportive, including 68 
administration of oral and intravenous fluids and electrolytes, management of co-infections and symptom 69 
control.3-5 EVD is recognised to cause marked biochemical abnormalities which may be amenable to simple 70 
interventions, potentially reducing the high case fatality rate (CFR).4,6-12 Due to the low-resource setting of 71 
outbreaks and risks associated with collecting and processing laboratory samples, few data exist on these 72 
abnormalities, mostly from animal models, small cohorts or case studies from resource-rich settings.6-9,11,13 73 
 74 
Kerry Town Ebola Treatment Centre (ETC), operated by Save the Children, opened on November 5th 2014 in 75 
Sierra Leone offering supportive care focused on fluid and electrolyte management, in accordance with 76 
World Health Organization (WHO) guidelines.3 This included haematology and biochemistry testing for all 77 
admissions from December 8th 2014. We report data on clinical presentation, laboratory abnormalities, and 78 
their association with mortality in patients admitted over a one month period. This data will assist in case 79 
management in centres without access to laboratory support, provide insight into the disease 80 
pathophysiology, corroborate animal models, and help identify priority areas for future research. 81 
 82 
Methods 83 
Study Design 84 
We conducted a cohort study of patients consecutively admitted to Kerry Town ETC between 8th December 85 
2014 and 9th January 2015. During this period only patients with EVD confirmed at other isolation or 86 
community care centers were admitted. We used a standard case definition as per WHO guidelines.2 All 87 
patients were included in the study except for those who were dead on arrival, or those who had no blood 88 
results within 24 hours of admission. Primary outcome measure was discharge from the ETC. 89 
 90 
Blood Analysis 91 
Samples were analysed at the on-site laboratory run by Public Health England and the UK Defence Medical 92 
Services (UK-DMS). The Piccolo Express® system (Abaxis, California, USA) was used to generate metabolic 93 
and liver function profiles. An assay with biochemistry and liver function profile was primarily used 94 
(Amylyte 13), though some samples were processed on a separate assay that included lactate, magnesium, 95 
calcium and phosphate but excluded liver function profile (Metlac 12). Laboratory scientists selected the 96 
assay based on availability, unless clinically requested. Haematology samples were processed using a 97 
Horiba ABX Micros ES60® analyser (Horiba, Montpellier, France). Reverse-transcriptase-polymerase-chain-98 
reaction (RT-PCR) assays for diagnosis of EBOV were performed using the Altona RealStar® Filovirus RT-PCR 99 
Kit (Altona, Hamburg, Germany), following inactivation and manual RNA extraction. Positive results were 100 
reported as Ct (cycle threshold) values. All patients had a repeat RT-PCR on admission.  101 
 102 
Data Collection 103 
All data was collected as part of routine patient care, and recorded on standardised forms, which were kept 104 
securely. Data extracted for research purposes was anonymised and stored on a password-protected 105 
database. The Sierra Leone Ethics and Scientific Review Committee provided study approval.  106 
 107 
Clinical Staging and management 108 
All patients were assigned a disease stage on admission according to their clinical features. The staging 109 
system was developed by the UK-DMS in reference to WHO guidelines and the proposed pathogenesis of 110 
EVD and is outlined in Table 1.3,12-15 Children were staged using a similar system, informally adapted to 111 
include paediatic indicators of dehydration as per WHO.3 Standardised therapy was administered to all 112 
patients based on disease stage. Targeted electrolyte replacement was provided based on biochemistry 113 
results. Patients were discharged once asymptomatic for 72 hours with negative repeat blood Ebola RT-114 
PCR. Acute Kidney Injury (AKI) was defined according to RIFLE criteria.16 To estimate baseline creatinine, we 115 
used the Modification of Diet in Renal Disease (MDRD) for adults,17 and the Schwartz calculation for 116 
children.18 For ALT and AST, ‘high’ was defined as 5-15 times the upper limit of normal (ULN), and ‘very 117 
high/severe’ was defined as >15 times ULN. EBOV RT-PCR Ct value (Ct) was categorised as low (<20 cycles) 118 
or high (≥20 cycles) with low Ct indicating high viral load. 119 
 120 
Statistical Analysis 121 
Descriptive analyses are reported as frequencies, proportions, means or medians. We used χ2, t-test and 122 
Wilcoxon rank-sum for comparisons. Risk factors for mortality were assessed using logistic regression. A 123 
priori variables, and variables associated with mortality in univariate analysis (at p<0.1) were assessed in a 124 
multivariate model. Interactions were assessed using likelihood ratio tests. Adjustment was not made for 125 
missing data since biochemical and haemotological variables were missing at random. Hypothesis tests 126 
were two-tailed (at p<0·05). Data was analysed using Stata (Statacorp, Texas, USA), v13. 127 
 128 
Role of the Funding Source 129 
The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or 130 
writing of the report. The corresponding author had full access to the data in the study and had final 131 
responsibility for the decision to submit for publication. 132 
 133 
Results 134 
During the study period, 150 patients were admitted with confirmed EVD. Additionally 6 non-EVD cases 135 
were referred and 4 patients died in transit. Absent laboratory samples were due to no sample being 136 
obtained on admission (n=8) and a laboratory isolator fault meaning no samples were processed from 26th-137 
29th December (n=24). Of the 118 included patients, 104 had haematology and 114 had biochemistry 138 
analysed. In these patients, absent tests were due to no haematology sample being taken (n=12), 139 
haematology sample inadequate for analysis (n=2) or no biochemistry sample taken (n=4). 101 patients had 140 
liver function analysed and 18 had lactate measured, with 5 having both.  141 
 142 
Baseline characteristics are described in Table 2. Among EVD cases, 52·5% were male. The mean age was 143 
25·9 years (sd 14·7). Children (<18 years) accounted for 32·2%. Median time from admission to discharge 144 
amongst survivors was 8 days (inter quartile range (IQR) 5-12) and median time from admission to death 145 
was 4 days (IQR 3-5). Patients without laboratory investigations were more likely to be under 5 years 146 
(p=0·003) and female (p=0·033) but otherwise had similar baseline characteristics to those with laboratory 147 
results. 148 
 149 
Mortality  150 
Overall CFR for the study period was 36·7% (55/150). CFR in those included in this study was 34·7% 151 
(41/118). CFR was non-significantly higher in men than women (40·3% vs. 28·6%. X2=1·79, p=0·181) and 152 
lower in children (23·7% vs. 40·0%, X2=3·02, p=0·082). Higher disease stage on admission was strongly 153 
associated with mortality (66·7%, 32·7% and 25·8% for stage 3, 2 and 1 respectively, p=0·001). Mean time 154 
from symptom onset to admission was shorter in patients who died than in survivors. There was no 155 
association between time from symptom onset and disease stage at admission.  156 
 157 
RT-PCR Ct values 158 
The mean Ct in positive patients was 21·4 cycles (sd 4·5), with 41·1% (46/112) having a low Ct. Low Ct on 159 
admission was strongly associated with mortality (65·2% vs. 13·6%, p<0·001). Fifteen patients were 160 
transferred following positive EBOV RT-PCR tests at the referring center, but tested negative at admission, 161 
despite remaining symptomatic. Their survival rate was 100%.   162 
 163 
Biochemistry 164 
Biochemistry results for the cohort are outlined in Table 3 and Figure 1. Creatinine levels were significantly 165 
higher in fatal than non-fatal cases (median 467µmol/L vs. 90µmol/L respectively, p<0·001, n=104). AKI was 166 
common, occurring in 50·0% (52/104) of cases. AKI occurred more commonly in fatal than non-fatal cases 167 
(81·3% vs. 18·1%, p<0·001) and when it did occur it was always severe (RIFLE-3). Incidence of AKI did not 168 
differ significantly by clinical stage (χ2= 9·83, p=0·610). Notably, 28·6% (9/31) of patients admitted with 169 
stage 1 disease had severe AKI.  170 
 171 
Abnormal potassium occurred in 33·0% (32/97) of admissions, with similar proportions having 172 
hypokalaemia and hyperkalaemia (19·6%, 19/97 and 13·4%, 13/97 respectively). Patients that died were 173 
more likely to have hyperkalaemia (35·7% vs. 4·4% of survivors, p<0·001), as were patients with AKI (26·7% 174 
with RIFLE-3 AKI vs. 6·5% with no AKI or RIFLE 1-2 AKI, p=0·007). Hyponatraemia was common (31·9%, 175 
36/113), but was not associated with outcome. Abnormal liver function was common, with 70·3% (71/101) 176 
having alanine transaminase (ALT) or aspartate transaminase (AST) >5 times ULN. Severe hepatitis (AST >15 177 
ULN) was more common in fatal than non-fatal cases (92·9% vs. 43·8% respectively, p<0·001). Median 178 
AST:ALT ratio was 2·3, and did not differ significantly between outcomes. Bilirubin was normal in 87·0% of 179 
cases.  180 
 181 
Raised creatinine kinase (CK) was common, and higher in fatal than non-fatal cases (median CK 2938 IU/L  182 
versus (vs.) 1519 IU/L, p=0·019, n=100). All cases with a normal CK survived. Fourteen cases had CK>5000 183 
IU/L (upper limit of our assay). Almost all cases with RIFLE-3 AKI had raised CK (97·1% vs. 78·3% with no AKI, 184 
p=0·014). Median C-reactive protein (CRP) was higher in fatal than non-fatal cases (median CRP 12.9 vs. 185 
69.5, p<0.001, n=100), and more fatal cases had CRP >100mg/L (46·9% vs. 8·8% in survivors, p<0·001). 186 
Lactate was raised in 91·7% (16/17) of cases. 187 
 188 
Haematology  189 
Haematology results for the cohort are outlined in Table 3 and Figure 1. Higher mean haemoglobin (Hb), 190 
haematocrit (Hct) and median platelet count were associated with mortality. Mean Hb, Hct and platelets in 191 
non-survivors versus survivors were 15·5g/dl vs. 13·5g/dl (p<0.001, n=103) 45·1 vs. 39·4% (p<0.001, n=100) 192 
and 146 x109/L vs. 197 x109/L (p=0·005, n=104) respectively. Thrombocytopaenia was more common 193 
amongst non-fatal cases (53·7% vs. 29·7%, p=0·019). Severe thrombocytopaenia (<50x109/L) was 194 
uncommon (2·9%, 3/104). 195 
 196 
Low median white cell count (WCC), lymphocyte count and granulocyte count also predicted survival. 197 
Median WCC was 15·8 x109/L vs. 7·9 x 109/L, (p<0·001, n=104) median lymphocytes were 4·2 x109/L vs. 2·2x 198 
109/L (p<0·001, n=104) and granulocytes were 11·5 x 109/L vs. 4·3 x 109/L (p=0.001, n=104) in non-survivors 199 
vs. survivors respectively. Granulocytosis was present in 42·3% (44/104) of cases, and lymphocytosis was 200 
more common in fatal cases (66·7% vs. 31·0% p=0·002).  Malaria co-infection was uncommon with 2·5%, 201 
3/114 having a positive Malaria RDT on admission. 202 
 203 
Risk factors for mortality 204 
In unadjusted analyses, the strongest risk factors for mortality were RIFLE-3 AKI (OR 19·7, 95%CI 6·7-57·4, 205 
vs. no AKI or RIFLE-1-2 AKI, p<0·001), severely raised AST (OR 16·7, 95%CI 3·7-76·5, vs. not severely raised 206 
AST, p<0·001), high haematocrit (OR 13·4, 95%CI 2·7-66·7, vs. normal, p=0·002), low EBOV RT-PCR Ct (OR 207 
11·9, 95%CI 4·7-30·1, vs. high Ct, p<0·001), hyperkalaemia (OR 11·1, 95%CI 2·7-45·7, vs. normal potassium, 208 
p=0·001), CRP >100mg/dl (OR 9·1, 95%CI 3·1-27·1, vs. CRP ≤100, p<0·001) and granulocytosis (OR 8·7, 209 
95%CI 2·9-26·5, vs. normal granulocytes, p<0·001). 210 
 211 
Although hyperkalaemia appeared to be associated with RIFLE-3 AKI, both remained associated with 212 
mortality in bivariate analyses (p<0·001). Similarly, haemoglobin and haematocrit were associated with 213 
each other, however haematocrit remained strongly associated with mortality after adjusting for 214 
haemoglobin (OR 26·9, 95%CI 2·5-289·3). CRP remained strongly associated with mortality (OR 16·5, 95%CI 215 
3·8-71·2), even after adjustment for granulocytosis. 216 
 217 
Multivariate analysis was undertaken using variables associated with mortality a priori (age, gender, RT-PCR 218 
Ct) or in univariate/bivariate analysis. Age was fitted as a continuous variable. Hyperkalaemia, CRP and 219 
granulocytosis appeared to become protective due to collinearity and were removed to improve stability.  220 
Hematocrit was removed because it had no effect. No interaction terms contributed to the model. The final 221 
model is shown in Table 4. The strongest independent risk factors for mortality were low EBOV RT-PCR Ct 222 
(OR 6·7, p=0·013, 95% CI 1·5-30.1) and RIFLE-3 AKI (OR 5·8, p=0·033, 95% CI 1·2-29·6). Disease stage on 223 
admission was not associated with mortality after adjustment for other risk factors. 224 
 225 
Discussion  226 
The natural history of EVD is well characterised with a gastrointestinal stage leading to significant 227 
hypovolaemia, systemic hypoperfusion and shock in inadequately fluid-resuscitated patients.4 The extent of 228 
multi-organ dysfunction syndrome—commonly involving the renal, hepatic, neurological and coagulation 229 
systems—varies from mild dysfunction to irreversible organ failure and death, but the pathogenesis of EVD 230 
remains poorly understood. Key to improving outcomes is the availability of routine biochemistry and 231 
haematological testing. Large observational studies are also required to compare data with animal models 232 
and support clinical trials of novel therapeutics.  233 
 234 
The majority of our patients were admitted with stage 2 or 3 disease (74/118), and had high levels of organ 235 
dysfunction and associated metabolic abnormalities. Fifty percent (52/104) of cases had AKI, and raised 236 
creatinine was associated with mortality, supporting earlier published data.6, 7 Importantly kidney 237 
dysfunction was not limited to later disease stage, supporting the role of IV fluid therapy in early disease.  238 
 239 
AKI is generally attributed to pre-renal causes.4,15 However, our results suggest AKI may be multifactorial, 240 
given the high prevalence in early disease where dehydration is a less common clinical finding. The role of 241 
rhabdomyolysis is unclear and worthy of further study given our almost universal findings of elevated CK 242 
(and its association with AKI), and disproportionately elevated AST. However CK was rarely elevated to 243 
levels associated with AKI, apart from a discreet number of patients who reached the ceiling of our assay 244 
measurement. Subsequent renal injury may also arise due to poor renal perfusion secondary to profound 245 
hypovolaemia from gastro-intestinal losses, or viral or secondary bacterial sepsis resulting in acute tubular 246 
necrosis.19 Microvascular damage from disseminated intravascular coagulation may also contribute; raised 247 
D-Dimer was a common finding in patients with Sudan Ebolavirus6 and autopsy of infected primates 248 
reported fibrinous cellular debris in glomerulus.20 Importantly, our data show that EVD-associated AKI can 249 
be managed successfully in this setting. 250 
 251 
Hepatocellular inflammation has previously been reported.8,9 Our data showed that most patients had 252 
elevated ALT/AST levels, which was associated with mortality. Normal bilirubin levels indicated fulminant 253 
hepatic failure is not a major feature consistent with the clinical syndrome observed. Elevated CRP and 254 
granulocytosis were also associated with mortality, which may reflect secondary bacterial infection, 20 255 
although all patients were treated with a third-generation cephalosporin from stage 2 of clinical disease.  256 
 257 
The data is the first reported on haematological abnormalities, and show that mortality was associated 258 
with higher haemoglobin and haematocrit. This may be a surrogate marker for intravascular fluid depletion, 259 
widely believed to be associated with poor outcomes.4 Thrombocytopaenia was common and occurred in 260 
45·2% of patients at presentation, but was rarely severe. It was not possible to measure coagulation in our 261 
cohort, and this should be a priority for future research given the frequency and poorly understood nature 262 
of haemorrhage in EVD. Semi-quantitative EBOV viral load measurement has been shown to be a useful 263 
predictor of mortality 8,12 and was associated with clinical outcome in our series.  264 
 265 
We report a number of study limitations.  The CFR is lower than others have reported. 7,10,11 While this may 266 
be due to a high-standard clinical care, it is possible that there is a survivor bias (i.e. patients with EVD more 267 
likely to survive were admitted to this ETC) since only patients confirmed to have Ebola were admitted 268 
during the study period, and there were time delays prior to ETC admission. This is supported by the finding 269 
that some patients were RT-PCR negative at admission, suggesting that they may have already cleared the 270 
virus. Caution should be used in comparing CFRs between settings. The finding that a shorter time from 271 
symptom onset to admission was associated with mortality may have been caused by recall bias and 272 
survivor bias; symptom onset date was collected from records sent with the patient, which were not always 273 
complete. Patients also presented to the ETC at different stages of illness, and had variable levels of 274 
treatment in holding centres prior to admission. 275 
 276 
Due to an isolator failure, 24 consecutive patients had no laboratory testing. The significance of this to our 277 
results is unclear. A number of the assays (AST, ALT, CK) were limited by their upper limits of detection, 278 
potentially underestimating the difference between groups. Additionally, baseline creatinine was estimated 279 
based on MDRD scores, which may have over- or under-estimated the prevalence of AKI.  280 
 281 
Conclusion 282 
Our data show that the provision of routine laboratory support to an ETC provides opportunity for 283 
improved understanding of disease pathophysiology, and correlation with clinical disease staging.  We 284 
demonstrate a previously unreported high prevalence of electrolyte imbalance and organ dysfunction in all 285 
stages of EVD. The ability to diagnose and treat these abnormalities at presentation and follow patients’ 286 
response to therapy is likely to improve survival.  287 
 288 
The most important aspects of supportive care are aggressive management of intravascular volume 289 
depletion, correcting electrolyte abnormalities, and preventing the complications of shock.21 These are 290 
underlying tenets of critical care medicine, which can and should be applied in this setting. Improving the 291 
provision of good supportive care including laboratory analysis is essential to further clarify the 292 
pathogenesis and pathophysiology of EVD in humans.  In parallel to ongoing intervention studies, this will 293 
inform evidence-based protocols to improve outcomes for this outbreak and the next. 294 
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 310 
Table 1 311 
Stage Clinical Features Typical Patient Standard Therapy  
1 Early/Mild Non-specific features. 
Pyrexia, weakness, 
lethargy, myalgia, 
arthritis 
Ambulatory, able to 
compensate for fluid 
losses via oral intake 
Oral Rehydration Solution 
Symptomatic treatment 
Zinc / Multivitamins 
Anti-malarials if RDT positive 
Targeted electrolyte replacement+ 
Treatment of hypoglycemia 
2 Gastrointestinal 
Involvement 
As above plus: 
diarrhoea, vomiting 
and/or abdominal pain 
Unable to compensate 
for fluid losses via oral 
intake due to emesis or 
loss of large volumes 
As per stage 1, plus: 
IV fluid therapy (3000-
6000ml/24h for adults, guided by 
fluid and electrolyte balance) 
IV Ceftriaxone*  
3 Complicated As above plus:  
hemorrhage, shock, 
neurological 
involvement and/or 
signs of organ failure 
Critically ill, usually 
hypovolaemic, often 
with confusion and/or 
seizures, bleeding.  
As per stage 1+2, plus: 
As clinically indicated: 
Sedation/anti-epileptics 
Vitamin K 
Fresh Frozen Plasma# 
RDT rapid malaria diagnostic test; IV intravenous. + Sodium, potassium, magnesium, calcium and phosphate replaced according to 312 
biochemistry results. *Ceftriaxone (2g once per day for adults) was given as an empirical 5 day course in all stage 2 and 3 patients. 313 
It was continued for longer or given to stage 1 patients if clinically indicated. # Fresh frozen plasma was given when hemorrhage 314 
occurred and when available. 315 
 316 
Table 1 Clinical staging system for Ebola virus disease used at Kerry Town ETC and subsequent standard 317 
clinical management.  318 
Table 2 319 
 Included in study No laboratory 
tests sent 
Survived Died  Total   
 Total 
number 
77 41 118 32 
Gender Male 37 (48·1) 25 (61·0) 62 (52·5) 10 
Female 40 (51·9) 16 (39·0) 56 (47·5) 22 
Age (years) Mean (sd) 23·2 (13·1) 31·0 (16·2) 25·9 (14·7) 25·1 (18·5) 
0-4 3 (3·9) 0 3 (2·5) 5 
5-14 20 (26·0) 8 (19·5) 28 (23·7) 5 
15-24 20 (26·0) 5 (12·2) 25 (21·2) 4 
25-34 20 (26·0) 11 (26·8) 31 (26·3) 9 
35-44 7 (9·1) 8 (19·5) 15 (12·7) 5 
45-80 7 (9·1) 9 (22·0) 16 (13·6) 4 
Time from 
symptom onset 
to admission 
(days) 
Mean (sd) 5·3 (3·2) 4·4 (2·9) 5·0 (3·1) 5·6 (2·2) 
1-3 16 (20·8) 13 (31·7) 29 (24·6) 4 
4-6 23 (29·9) 14 (34·1) 37 (31·4) 12 
≥7 14 (18·2) 3 (7·3) 17 (14·4) 7 
Unknown  24 (31·2) 11 (26·8) 35 (29·6) 9 
Stage at 
admission 
Stage 1 23 (29·9) 8 (19·5) 31 (26·3) 7 
Stage 2 47 (61·0) 25 (61·0) 72  (61·0) 16 
Stage 3 4 (5·2) 8 (19·5) 12 (10·2) 7 
Unknown 3 (3·9) 0 3 (2·5) 2 
Ebola RT-PCR at 
admission  
Positive 62 (80·5) 41 (100·0) 103 (87·3) 30 
Negative 15 (19·5) 0 15 (12·7) 1 
No result 0 0 0 1 
Malaria RDT Positive 1 (1·3) 2 (4·9) 3 (2·5) 1 
Negative  72 (93·5) 39 (95·1) 111 (94·1) 29 
Unknown 4 (5·2) 0 4 (3·4) 2 
Data are numbers (column %) unless otherwise stated. RT-PCR reverse-transcriptase-polymerase-chain-reaction; RDT rapid malaria 320 
diagnostic test.  321 
 322 
Table 2 Characteristics of patients with confirmed Ebola virus disease admitted to Kerry Town ETC during 323 
the study period  324 
Table 3 325 
Haematology 
    Survived Died Total Test 
Haemoglobin Mean g/dL (sd)  13·5 (2·1) 15·5 (2·6) 14·2 (2·5) p<0·001* 
  Anemia n (%) 
20/66 
(30·3) 
5/37 
(13·5) 
25/103 
(24·3) 
p=0·057# 
Haematocrit 
  
  
Mean % (sd)  39·4 (6·6) 45·1 (7·5) 41·4 (7·5) p<0·001* 
Raised, n(%) 2/64 (3·1) 
13/36 
(36·1) 
15/100 
(15·0) 
p<0·001# 
Low, n(%) 
29/64 
(45·3) 
7/36 
(19·4) 
36/100 
(36·0) 
Platelets 
Median x109/L (IQR) 
146 (108-
219) 
197 (145-
346) 
155 (119-
247) 
P=0·005$ 
Thrombocytopaenia, 
n(%) 
36/67 
(53·7) 
11/37 
(29·7) 
47/104 
(45·2) 
p=0·019# 
White blood 
cells 
Median x109/L (IQR) 
7·9 (4·8-
12·4) 
15·8 (8·6-
21·7) 
10·0 (5·2-
16·0) 
p<0·001$ 
Raised, n(%) 
21/67 
(31·3) 
25/37 
(67·6) 
46/104 
(44·2) 
p=0·001# 
Low, n(%) 
12/67 
(17·7) 
5/37 
(13·5) 
17/104 
(16·4) 
Lymphocytes  
Median x109/L (IQR) 
2·2 (1·5-
3·7) 
4·2 (2·2-
6·6) 
2·6 (1·6-
4·4) 
p<0·001$ 
Raised, n(%) 
19/67 
(28·4) 
24/37 
(64·9) 
43/104 
(41·4) p=0·001# 
Low, n(%) 7/67 (10·4) 1/37 (2·7) 8/104 (7·7) 
Granulocytes 
Median x109/L (IQR) 
4·3 (2·5-
8·0) 
11·5 (4·9-
14·0) 
5·7 (2·8-
11·0) 
p=0·001$ 
Raised, n(%) 
19/67 
(28·4) 
25/37 
(67·6) 
44/104 
(42·3) 
p<0·001# 
Low, n(%) 
15/67 
(22·4) 
7/37 
(18·9) 
22/104 
(21·2) 
Viral Load 
RT-PCR Cycle 
time 
Mean n (sd)*  
 
23·4 
(4·3), 60 
18·3 (2·7), 
39 
21·4 (4·5), 
99 
p<0·001* 
  Low, n(%) 
16/73 
(21·9) 
30/39 
(76·9) 
46/112 
(41·1) 
p<0·001# 
Biochemistry 
Creatinine 
Median µmol/L 
(IQR)  
90 (58-
161) 
467 (225-
754) 
121 (65-392) P<0·001$ 
RIFLE-1, n(%) 
5/72 
(6·9) 
0/32 5/104 (4·8) 
p<0·001# RIFLE-2, n(%) 
8/72 
(11·1) 
0/32 8/104 (7·7) 
RIFLE 3, n(%) 
13/72 
(18·1) 
26/32 
(81·3) 
39/104 
(37·5) 
Potassium  
Mean mmol/L (sd) 4·0 (0·7) 4·8 (0·9) 4·2 (0·9) p<0·001* 
Raised, n(%) 
3/69 
(4·4) 
10/28 
(35·7) 
13/97 (13·4) 
p<0·001# 
Low, n(%) 
16/69 
(23·2) 
3/28 (10·7) 19/97 (19·6) 
Sodium  
Mean mmol/L (sd) 
129·8 
(4·6) 
128·5 (5·8) 129·4 (5·1) p=0·182* 
Low, n(%) 
22/76 
(30·0) 
14/37 
(37·8) 
36/113 
(31·9) 
p=0·341# 
Lactate Mean mmol/L (sd) 4·0 (1·4) 4·5 (0·6) 4·2 (1·2) p=0·521* 
 Raised, n(%) 
11/12 
(91·7) 
5/5 (100·0) 16/17 (94·1) p=0·506# 
Total dissolved 
CO2 
Median mmol/L 
(IQR) 
22 (17-
28) 
17 (11-18) 20 (15-23) P=0·035$ 
 Low, n(%) 
3/12 
(25·0) 
4/6 (66·7) 7/18 (38·9) p=0·087# 
Liver function tests 
Alanine 
transaminase 
(ALT) 
Median IU/L (IQR) 
192 (86-
371) 
577 (314-
1195) 
253 (121-
594) 
P<0·001$ 
High, n(%) 
21/68 
(30·9) 
16/33 
(48·5) 
37/101 
(36·6) 
p<0·001# 
Very high, n(%) 
5/68 
(7·4) 
11/33 
(33·3) 
16/101 
(15·8) 
Aspartate 
transaminase 
(AST) 
Median IU/L (IQR) 
348 (129-
1254) 
>2000 
(1491-
>2000) 
867 (168-
>2000 
P<0·001$ 
High, n(%) 
11/64 
(17·2) 
2/28 (7·1) 13/92 (14·1) 
p<0·001# 
Very high, n(%) 
28/64 
(43·8) 
26/28 
(92·9) 
54/92 (58·7) 
AST:ALT ratio Median (IQR), n 
2·2 (1·4-
3·3) 
3·1 (1·6-
3·5) 
2·4 (1·4-3·4) p=0·259$ 
Creatinine 
kinase 
Median IU/L (IQR), n 
1519 
(367-
3454) 
2938 
(1137-
3400) 
1949 (589-
3400) 
P=0·019$ 
High, n(%) 
51/68 
(75·0) 
32/32 
(100·0) 
83/100 
(83·0) 
p=0·002# 
C-reactive 
protein 
Median mg/L (IQR) 
12·9 (5·0-
29·4) 
69·5 (22·5-
147·0) 
21·4 (6·0-
77·0) 
P<0·001$ 
High, n(%) 
6/68 
(8·8) 
15/32 
(46·9) 
21/100 
(21·0) 
p<0·001# 
All data are numbers (column %) unless otherwise stated· *median only presented for RT-PCR results that were positive·* 
denotes p-value from t-test, #deontes p-value from χ2 test, $deontes p-value from Wilcoxon rank-sum·  Definitions are as follows; 
RT-PCR - reverse-transcriptase-polymerase-chain-reaction, anemia - as per WHO definitions, 22 thrombocytopaenia <150 x x109/L, 
raised white cell count >11 x109/L, low white cell count <4 x109/L, raised lymphocytes >3·2 x109/L, low lymphocytes <1 x109/L, 
raised granulocytes >7·5 x109/L, low granulocytes <2·5 x109/L, low RT-PCR Cycle time <20 cycles, RIFLE-1 AKI 1·5-2 x baseline 
creatinine, RIFLE 2 AKI 2-3 x baseline creatinine, RIFLE-3 AKI >3 x baseline creatinine, raised potassium >5·1 mmol/L, low 
potassium <3·6mmol/l, raised Lactate >2·1 mmol/l, low total dissolved CO2 <18 IU/L, high ALT >240 - ≤720 IU/L, very high ALT 
>720 IU/L, high AST >175 - ≤525 IU/L, very high AST >525 IU/L, high creatinine kinase >380 U/L and high c-reactive protein >100 
mg/l·  
 
Table 3 Laboratory results and abnormalities in patients admitted to Kerry Town ETC with confirmed 
Ebola 
 326 
Figure 1 327 
 328 
ALT alanine transaminase; AST asparate transaminase; CK creatinine kinase; CRP C-reactive protein; Cycle time is Ebolavirus 329 
reverse-transcriptase-polymerase-chain reaction cycle time. P-values are from t-tests (potassium and sodium) and Wilcoxon rank-330 
sum tests (all others). Shaded area indicates normal range for the UK based population. 331 
Figure 1 Box plots of laboratory results from patients admitted to Kerry Town ETC; results are presented by 332 
outcome.  333 
  334 
 335 
Table 4 336 
OR odds ratio; RT-PCR reverse-transcriptase-polymerase-chain-reaction; AST aspartate transaminase, AKI acute kidney injury. P-337 
values are from likelihood ratio tests. Age was treated as a continuous variable.  338 
 339 
Table 4 Factors associated with mortality in patients with previously confirmed Ebola virus admitted to 340 
Kerry Town ETC 341 
 342 
 343 
 Univariate analysis Multivariate analysis 
 OR (95% CI) p-value OR (95% CI) p-value 
Female Gender 0·59 (0·27-1·28) 0·182 0·33 (0·07-1·63) 0·174 
Age 1·04 (1·01-1·07) 0·008 1·01 (0·95-1·06) 0·819 
Disease stage 2.16 (1.08-4.32) 0.029 1.40 (0.41-4.84) 0.593 
RT-PCR Cycle 
threshold <20 
11·88 (4·69-30·06) <0·001 6·72 (1·50-30.07) 0·013 
RIFLE-3 AKI 19·67 (6·73-57·43) <0·001 5·84 (1·15-29·58) 0·033 
AST>525 U/L 16·71 (3·65-76·47) <0·001 6.95 (0·70-68·86) 0·097 
Potassium >5·1 
mmol/L 
11·11 (2·70-45·66) <0·001 -  
CRP >100mg/dl 9·12 (3·07-27·07) <0·001 -  
Granulocytes 
>7·5 x109/L 
8·68 (2·85-26·45) <0·001 -  
High haematocrit 13·41 (2·70-66·67) 0·002 -  
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